A Phase 1/2a Study of K-1728 in Advanced Solid Tumors

Study acronym: PIKYMA-01
StatusNot Yet Recruiting
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This first-in-human, open-label, multicenter study evaluates K-1728 administered as monotherapy and in combination in participants with advanced or metastatic solid tumors. The study assesses the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of K-1728.
Trial Details
NCT Number NCT07861932
Lead Sponsor KymaThera, Inc.
Conditions
(from sponsor)		 Breast Neoplasms, Solid Tumors, PIK3CA Gene Mutation
Related terms Breast Neoplasms
Enrollment 110 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov